Baylor College of Medicine

TBCRC 047: Innovative Combination Immunotherapy for Metastatic Triple-Negative Breast Cancer (H-46124)

Description

Content

The purpose of this study is to determine if the investigational combination of avelumab with several different drugs - utomilumab, PF-04518600 or binimetinib - is safe and effective for treating patients with metastatic triple-negative breast cancer.

Contact

Kankana Chava

Phone 1: 713–798–1911

IRB: H-46124

Status:

Active

Created:

Back to topback-to-top